Cyclophosphamide has drastically enhanced the expectancy and quality of life of cancer
patients. However, it is accompanied by diverse neurological complications which are …

Cyclophosphamide (CYP) is an anti-neoplastic agent as well as an immunosuppressive
agent. In order to elucidate the alteration in adult hippocampal function following acute CYP …

Cyclophosphamide (CYP) is a classic DNA-interacting anticancer agent with broad
application in chemotherapy. However, CYP cerebral neurotoxicity is a worrisome side effect …

Chemobrain is a condition that negatively affects cognition in cancer patients undergoing
active chemotherapy, as well as following chemotherapy cessation. Chemobrain is also …

Postchemotherapy cognitive impairment, or PCCI, is a common complaint, particularly
among breast cancer patients. However, the exact nature of PCCI appears complex. To …

There is accumulating clinical evidence that chemotherapeutic agents induce neurological
side effects, including memory deficits and mood disorders, in cancer patients who have …

Breast cancer (BC) is the most common cancer among women. Fortunately, BC survival
rates have increased because the implementation of adjuvant chemotherapy leading to a …

Background: Cyclophosphamide (CPA) is the most widely prescribed cancer
chemotherapeutic agent which shows serious neurotoxic side effect. Generation of reactive …

Chemotherapy frequently results in neurocognitive deficits that include impaired learning
and memory. Thus, it is important to prevent or ameliorate the persistence of cognitive …

Novel treatments, screening, and detection methods have prolonged the lives of numerous
cancer patients worldwide. Unfortunately, existing and many promising new …